Clodronate disodium Chemical Properties

Melting point:

>330°C

storage temp. 

room temp

solubility 

Freely soluble in water, practically insoluble in ethanol (96 per cent), slightly soluble in methanol.

form 

Solid

color 

White to Off-White

Water Solubility 

water: 49.00-51.00mg/mL, clear, colorless

InChIKey

HJKBJIYDJLVSAO-UHFFFAOYSA-L

CAS DataBase Reference

22560-50-5(CAS DataBase Reference)

Safety Information

WGK Germany 

3

RTECS 

SZ7640700

HS Code 

29319090

Toxicity

mouse,LD50,intraperitoneal,780mg/kg (780mg/kg),British UK Patent Application. Vol. #2096889,

MSDS

• Language:English Provider:SigmaAldrich

Clodronate disodium Usage And Synthesis

Description

Clodronate disodium is a bone resorption inhibitor, useful as adjunct therapy in the treatment of osteolytic bone metastases and malignant hypercalcemia.

Chemical Properties

White Solid

Originator

Proctor & Gamble (USA)

Uses

Clodronic Acid Disodium Salt Hydrate is a bisphosphonate antiresorptive agent; bone resorption inhibitor.

Definition

ChEBI: The disodium salt of clodronic acid. It inhibits bone resorption and soft tissue calcification, and is used (generally as the tetrahydrate) as an adjunct in the treatment of severe hypercalcaemia associated with malignancy, and in the management of osteoly ic lesions and bone pain associated with skeletal metastases.

brand name

Bonefos (Leiras Oy, Finland).

Hazard

Moderately toxic by ingestion.

Biochem/physiol Actions

Analog of pyrophosphate ion that inhibits the osteoclastic activity leading to bone resorption and osteoporosis. The compound is used in cancer research, especially in skeletal metastases and breast carcinoma. When entrapped in liposomes, it is used for macrophage-selective depletion (macrophage "suicide" technique), especially in spleen and liver. Found also to inhibit collagenase and matrix metalloproteinase1.

Clinical Use

Bisphosphonate: Management of osteolytic lesions, hypercalcaemia and bone pain associated with skeletal metastases in patients with breast cancer or multiple myeloma

Safety Profile

A poison by intravenous route. Moderately toxic by ingestion, intraperitoneal routes. When heated to decomposition it emits toxic vapors of PO, and Cl-

Drug interactions

Potentially hazardous interactions with other drugs
Cytotoxics: concentration of estramustine increased.

Metabolism

Clodronate is not metabolised.
Over 70% of an intravenous dose is excreted unchanged in the urine within 24 hours, the remainder being sequestered to bone tissue. The substance which is bound to bone is excreted more slowly, and the renal clearance is about 75% of the plasma clearance.

Clodronate disodium(22560-50-5)Related Product Information

• Sodium Monofluorophosphate
• Ethylenediaminetetraacetic acid disodium salt
• Ethyl 2-(Chlorosulfonyl)acetate
• Disodium pamidronate
• CLODRONIC ACID
• Citric acid
• Folic acid
• Ascoric Acid
• Chrysene
• Disodium clodronate tetrahydrate
• DMDP,DMDP[(2R,5R)-BIS(HYDROXYMETHYL)-(3R,4R)-DIHYDROXYPYRROLIDINE],2,5-Dideoxy-2,5-imino-D-mannitol, DMDP
• DMDP-TAT-59
• METHYLENEBISPHOSPHONIC ACID-P,P'-DISODIUM SALT
• CHLOROMETHYLPHOSPHONIC ACID
• (dichloromethyl)phosphonic acid
• Clodronate disodium